Published in Gastroenterology on August 16, 2010
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut (2013) 1.88
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep (2010) 0.92
Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol (N Y) (2012) 0.92
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis (2011) 0.92
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther (2011) 0.91
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clin Mol Hepatol (2012) 0.80
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therap Adv Gastroenterol (2012) 0.79
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr (2011) 0.77
Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients. Gastroenterology (2011) 0.77
An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis C. Hepat Mon (2015) 0.77
Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver (2015) 0.76
Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat (2012) 0.76
Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy. Pharmacoeconomics (2015) 0.76
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One (2016) 0.75
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients. Clin Mol Hepatol (2012) 0.75
Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection. World J Gastroenterol (2014) 0.75
Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. Int J Prev Med (2014) 0.75
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord. BMC Infect Dis (2015) 0.75
Progression of liver diseases. Hepat Mon (2012) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Liver cirrhosis. Lancet (2008) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
The devil is in the third year: a longitudinal study of erosion of empathy in medical school. Acad Med (2009) 5.15
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16